This content is in French.
Progeria: a new therapeutic avenue?
20 février 2025
#Progeria #PrematureAging #CRM1 #Selinexor #Senescence #TargetedTherapy
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder that causes premature aging. It is triggered by a mutation in the LMNA gene, leading to the abnormal production of progerin. This protein accumulates in the cell nucleus, disrupting cellular function and accelerating aging. Affected children develop severe cardiovascular complications, leading to early death, usually before the age of 15.
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder that causes premature aging. It is triggered by a mutation in the LMNA gene, leading to the abnormal production of progerin. This protein accumulates in the cell nucleus, disrupting cellular function and accelerating aging. Affected children develop severe cardiovascular complications, leading to early death, usually before the age of 15.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Soto‐Ponce, A., et al. (2025). Targeting CRM1 for Progeria Syndrome Therapy. Aging Cell, e14495
View the source
